N-Acetyl Cysteine (NAC) 관련 Helicobacter pylori Infection
CNAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.
<\/script>\n`;
},
get iframeSnippet() {
const domain = 'gutcited.com';
const params = 'ingredient\u003Dn\u002Dacetyl\u002Dcysteine\u0026condition\u003Dh\u002Dpylori';
return ``;
},
get activeSnippet() {
return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet;
},
copySnippet() {
navigator.clipboard.writeText(this.activeSnippet).then(() => {
this.copied = true;
setTimeout(() => { this.copied = false; }, 2000);
});
}
}"
@keydown.escape.window="open = false"
@click.outside="open = false">
C
결론
NAC (600-1,200 mg/day) may improve H. pylori eradication rates by disrupting biofilm. Small studies show improved eradication when combined with standard therapy.
Key Study Findings
In Vitro
Berberrubine inhibits Helicobacter pylori by inducing oxidative stress and impairing membrane integrity.
Dose: MIC 11 μg/mL
vs: None
Outcome: anti-Helicobacter pylori activity
효과: None
None
대상 집단: None
Other
Correction to "N-Acetylcysteine Reduces ROS-Mediated Oxidative DNA Damage and PI3K/Akt Pathway Activation Induced by Helicobacter …
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: Published erratum (correction notice)
Review
Posttranslational modifications in Helicobacter pylori-associated gastric pathogenesis: Bridging inflammation and carcinogenesis.
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Other
Liposomal Drug Delivery against Helicobacter pylori Using Furazolidone and N-Acetyl Cysteine in Augmented Therapy.
Dose: None
vs: None
Outcome: Cancer outcomes
효과: None
None
대상 집단: Cancer patients
In Vitro
Helicobacter pylori infection selectively attenuates endothelial function in male mice via exosomes-mediated ROS production.
Dose: None
vs: None
Outcome: choline levels/cognition
효과: None
None
대상 집단: Mice
Other
α-Lipoic Acid Inhibits Apoptosis by Suppressing the Loss of Ku Proteins in Helicobacter pylori-Infected Human …
Dose: None
vs: None
Outcome: None
효과: None
None
대상 집단: None
Key Statistics
3
연구
250
참여자
↑
Positive
C
등급
Referenced Papers
mLife
2026
Biochimica et biophysica …
2025
1 인용
Oxidative medicine and …
2025
Pharmaceutics
2024
8 인용
Frontiers in cellular …
2023
7 인용
Frontiers in cardiovascular …
2022
27 인용
Nutrients
2022
11 인용
Microbial drug resistance …
2020
34 인용
Therapeutic advances in …
2020
7 인용
Synthesis of Fucose Derivatives with Thiol Motifs towards Suicide Inhibition of Helicobacter pylori.
Other
Molecules (Basel, Switzerland)
2020
Expert review of …
2019
85 인용
The Cochrane database …
2019
21 인용
Oxidative medicine and …
2018
93 인용
The effect of antioxidants on Helicobacter pylori eradication: A systematic review with meta-analysis.
Meta-Analysis
Helicobacter
2018
18 인용
N-acetylcysteine prevents the development of gastritis induced by Helicobacter pylori infection.
Other
Journal of microbiology …
2017
16 인용
Cell host & …
2016
101 인용
Helicobacter
2016
60 인용
Nutrition research (New …
2016
25 인용
Molecular carcinogenesis
2016
18 인용
Gut and liver
2016
17 인용
Pathogens and disease
2015
64 인용
World journal of …
2015
21 인용
Journal of cancer …
2013
10 인용
Alimentary pharmacology & …
2012
104 인용
Clinical and experimental …
2012
1 인용
Journal of clinical …
2011
34 인용
Clinical gastroenterology and …
2010
103 인용
Pharmaceutical biology
2010
16 인용
Probiotics and antimicrobial …
2010
9 인용
American family physician
2009
Helicobacter
2007
130 인용
World journal of …
2007
77 인용
Journal of agricultural …
2007
44 인용
American journal of …
2007
11 인용
Digestive diseases and …
2004
53 인용
Digestive diseases and …
2004
4 인용
Digestive diseases and …
2003
69 인용
Annals of the …
2002
30 인용
Journal of environmental …
2002
Pharmacological research
2001
25 인용
Schweizerische medizinische Wochenschrift
1994
22 인용
Dosage & Usage
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units
일반적으로 사용되는 용량
- general:
- 600-1,200 mg/day in divided doses
- hpyloriadjunct:
- 600 mg twice daily alongside standard triple therapy
- antioxidantsupport:
- 600-900 mg/day
상한량: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
연구에서 사용된 용량
| 용량 | 기간 | 효과 | N |
|---|---|---|---|
| MIC 11 μg/mL | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Positive | -- |
| None | -- | Mixed | -- |
| None | -- | Mixed | -- |
| None | -- | Negative | -- |
| None | -- | Positive | -- |
권장 복용 시간: With or without food; divide doses throughout the day
Safety & Side Effects
보고된 부작용
- ⚠ Nausea and vomiting (most common, especially at higher doses)
- ⚠ Diarrhea
- ⚠ Unpleasant sulfur taste/odor
- ⚠ Headache
알려진 상호작용
- ● Nitroglycerin (NAC may enhance vasodilatory effects; risk of hypotension)
- ● Activated charcoal (may reduce NAC absorption)
- ● Anticoagulants (NAC may have mild antiplatelet effects)
- ● ACE inhibitors (additive hypotensive effect with nitroglycerin combination)
일일 최대 섭취 허용량: Generally well-tolerated up to 1,800 mg/day; higher doses used in clinical settings
건강기능식품을 복용하기 전에 반드시 의료 전문가와 상담하십시오.
Frequently Asked Questions
Does N-Acetyl Cysteine (NAC) help with Helicobacter pylori Infection?
Based on 3 studies with 250 participants, there is limited but promising evidence that N-Acetyl Cysteine (NAC) may support Helicobacter pylori Infection management. Our evidence grade is C (Some Evidence).
How much N-Acetyl Cysteine (NAC) should I take for Helicobacter pylori Infection?
Studies have used various dosages. A commonly studied range is 600-1,200 mg/day in divided doses. Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of N-Acetyl Cysteine (NAC)?
Reported side effects may include Nausea and vomiting (most common, especially at higher doses), Diarrhea, Unpleasant sulfur taste/odor, Headache. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for N-Acetyl Cysteine (NAC) and Helicobacter pylori Infection?
We rate the evidence as Grade C (Some Evidence). This rating is based on 3 peer-reviewed studies with 250 total participants. The overall direction of effect is positive.
Related Evidence
관련 다른 성분: Helicobacter pylori Infection
N-Acetyl Cysteine (NAC) 다른 건강 상태에 대한 근거
FDA 면책 조항: 이 내용은 미국 식품의약국(FDA)의 평가를 받지 않았습니다. 이 웹사이트의 제품 및 정보는 질병의 진단, 치료, 완치 또는 예방을 목적으로 하지 않습니다. 제시된 근거 등급은 발표된 동료 심사 연구에 대한 우리의 분석에 기반하며, 의학적 조언을 구성하지 않습니다. 건강기능식품 복용을 시작하기 전에 반드시 의료 전문가와 상담하십시오.